AlphaQuest LLC Has $2.17 Million Position in Boston Scientific Corporation $BSX

Key Points

• AlphaQuest LLC reduced its stake in Boston Scientific Corporation by 23%, selling 6,418 shares and retaining 21,540 shares valued at approximately $2.17 million.
• Several analysts raised their target prices on Boston Scientific, with Truist Financial setting a new target at $125.00, indicating a positive outlook for the company.
• Insider transactions saw significant activity, with executives selling a total of 345,029 shares of Boston Scientific stock worth nearly $36 million in the last 90 days.

AlphaQuest LLC cut its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 23.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,540 shares of the medical equipment provider's stock after selling 6,418 shares during the period. AlphaQuest LLC's holdings in Boston Scientific were worth $2,173,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE raised its holdings in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares in the last quarter. First Trust Advisors LP raised its holdings in Boston Scientific by 160.9% during the fourth quarter. First Trust Advisors LP now owns 511,920 shares of the medical equipment provider's stock worth $45,725,000 after purchasing an additional 315,708 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in Boston Scientific by 21.2% during the fourth quarter. MML Investors Services LLC now owns 107,648 shares of the medical equipment provider's stock worth $9,615,000 after purchasing an additional 18,840 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 0.1%

NYSE BSX traded down $0.06 on Wednesday, reaching $106.33. The stock had a trading volume of 2,598,469 shares, compared to its average volume of 7,504,064. Boston Scientific Corporation has a 1 year low of $79.03 and a 1 year high of $108.94. The business has a 50 day moving average price of $104.27 and a 200 day moving average price of $102.15. The company has a market capitalization of $157.55 billion, a price-to-earnings ratio of 63.22, a P/E/G ratio of 2.53 and a beta of 0.66. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent research reports. Truist Financial boosted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Oppenheimer upped their price objective on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. UBS Group lifted their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $117.50.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock valued at $35,976,603 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.